Key points are not available for this paper at this time.
Frequent intravesical instillations can significantly impair QoL, particularly among older patients. While emerging therapies and supportive strategies may help alleviate treatment burden, clinical decision-making must carefully balance QoL with oncologic outcomes. Future research should prioritize personalized approaches that integrate both clinical efficacy and patient-reported outcomes (PROs).
Griebsch et al. (Thu,) studied this question.